Disability

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Patients for Patient Safety US Receives $100,000 to Launch ‘Project PIVOT,’ a Novel, Patient-Centered Initiative to Improve Healthcare

WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024 / The Patient-Centered Outcomes Research Institute (PCORI) awarded Patients for Patient Safety…

2 years ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and…

2 years ago

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals…

2 years ago

IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics…

2 years ago

Discovery World on Market Partners for Blue Star Museum Program

PARKERSBURG, WV / ACCESSWIRE / May 3, 2024 / Discovery World on Market is teaming up with Fight4Vets and Jan…

2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit

MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low…

2 years ago

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events

Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage…

2 years ago